Introduction {#Sec1}
============

Omnitrope^®^ (Sandoz) is a recombinant human growth hormone (rhGH) approved by the European Medicines Agency in 2006; approval was granted via the biosimilar regulatory pathway, on the basis of comparable quality, safety, and efficacy to the reference product (Genotropin^®^, Pfizer) \[[@CR1]\]. Omnitrope is licensed for use to treat growth disturbances in the following pediatric indications: growth hormone deficiency (GHD), Turner syndrome, chronic renal insufficiency, Prader--Willi syndrome, and short children born small for gestational age (SGA) \[[@CR2]\].

Depending on the definition used, up to 10% of all live births each year are described as SGA \[[@CR3]\]. Most children born SGA achieve appropriate catch-up growth by the age of 2--3 years, although approximately 10% do not; these children are at heightened risk of short stature in adulthood \[[@CR3], [@CR4]\]. In addition to short stature, SGA infants may be predisposed to altered body composition and (in adult life) hypertension and cardiovascular disease \[[@CR4]--[@CR7]\]. Data from epidemiological studies indicate that children born SGA are also at increased risk of insulin resistance and type 2 diabetes in adulthood \[[@CR8], [@CR9]\]. rhGH therapy has been shown to induce transient resistance to the actions of insulin in children; therefore, concerns exist over the diabetogenic potential of rhGH therapy in children born SGA.

There are only limited data on the long-term use of rhGH in SGA children and the impact of treatment on diabetes in this population. This ongoing, long-term, phase IV, multicenter study with Omnitrope is the largest prospective clinical study so far conducted of rhGH in SGA patients \[[@CR10]\]. In this paper, data are reported for patients who have completed 2 years of treatment.

Methods {#Sec2}
=======

Study Design and Patients {#Sec3}
-------------------------

The study design has been reported in detail previously \[[@CR10]\]. Briefly, this is an ongoing, prospective, open-label, non-comparative, multicenter, phase IV study. Key inclusion criteria are as follows: prepubertal (Tanner stage I) children born SGA with growth disturbances defined as current height standard deviation score (HSDS) \<−2.5 and parental adjusted SDS \<−1; birth weight and/or length \<−2 SDS \[[@CR11]\]; failure of catch-up growth \[height velocity (HV) SDS \<0 during the last year\] by 4 years of age or later; availability of height records between 18 months and 6 months before the start of treatment. Key exclusion criteria include onset of puberty, closed epiphyses, type 1 or 2 diabetes mellitus, fasting blood glucose \>100 mg/dL (5.6 mmol/L), and abnormal 2-h oral glucose tolerance test \[OGTT; \>140 mg/dL (7.8 mmol/L)\].

For each participating center, an Independent Ethics Committee or Institutional Review Board reviewed and approved the study protocol, including all amendments. All procedures complied with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

Study Objectives {#Sec4}
----------------

The primary study objective is to assess the long-term effect of Omnitrope treatment on the development of diabetes in short children born SGA. Secondary objectives include evaluation of efficacy through changes in height parameters, incidence and severity of adverse events (AEs), occurrence of malignancies during treatment, and detection of anti-rhGH antibodies during treatment.

Study Treatment {#Sec5}
---------------

Patients are treated with Omnitrope 0.035 mg/kg/day administered subcutaneously. If insulin-like growth factor I (IGF-I) exceeds +2SD compared to references for age and pubertal status, the ratio of IGF-I to insulin-like growth factor-binding protein 3 (IGFBP-3) is taken into account. If the IGF-I/IGFBP-3 ratio also exceeds +2SD, a dose reduction is recommended. The extent of the dose reduction is at the discretion of the investigator. Dose increases are only permitted based on an increase in body weight.

Treatment was discontinued after 1 year if HVSDS was below +1, in which case the patient was classed as a non-responder. Responders continue treatment until HV \<2 cm/year, and if confirmation is required, bone age (BA) \>14 years (girls) or \>16 years (boys).

Timing of Study Assessments {#Sec6}
---------------------------

Height is measured in cm and HV calculated. HSDS and HVSDS (based on the relevant country-specific reference tables) are assessed at baseline and at 3-month intervals throughout the first 2 years, and every 6 months thereafter. X-rays of the left hand and wrist are used to determine BA at baseline and once yearly thereafter.

IGF-I and IGFBP-3 are measured at screening by a central laboratory, followed by every 3 months during the first year and every 6 months thereafter. IGF-I and IGFBP-3 serum levels are categorized as low (\<−2 SD), normal, or high (\>+2 SD), compared with the normal ranges for age and sex \[[@CR12]\]. Fasting plasma glucose, insulin levels, and glycated hemoglobin (HbA~1c~) are measured at baseline, 6 months, 12 months, and annually thereafter. OGTTs are conducted at the same time points. All AEs are registered at each visit.

Antibodies to GH were measured centrally using a validated radio-binding assay for non-neutralizing anti-GH antibodies.

Patient Populations and Statistical Analyses {#Sec7}
--------------------------------------------

The intention-to-treat population consisted of all subjects enrolled in the study who received at least one dose of study medication. The safety population comprised all patients who received at least one dose of study medication and had at least one post-baseline safety assessment.

The current analysis includes data from baseline up to the 2-year visit. Analyses were performed using SAS Version 9.1.3 or later (SAS Institute Inc., Cary, NC, USA). Descriptive statistics were used to evaluate homeostasis model assessment (HOMA), quantitative insulin sensitivity check index (QUICKI), IGF-I, IGFBP-3, and SDS for IGF-I and IGFBP-3. *P* values were calculated using paired *t* tests, with statistical significance defined as *P* \< 0.05.

Results {#Sec8}
=======

Patients {#Sec9}
--------

Patients have been recruited and treated at 32 centers in 7 countries (Poland, Romania, Hungary, Czech Republic, Germany, Belgium, Georgia). In total, 278 children (148 males, 130 females) have been enrolled and received study medication; 249 have completed 2 years of treatment. Twenty-nine children have therefore been withdrawn from the study (non-responders, *n* = 13; withdrawal of consent, *n* = 11; loss to follow-up, *n* = 3; protocol violation, *n* = 1; not taking medication, *n* = 1). Table [1](#Tab1){ref-type="table"} shows data on patient demographics and baseline characteristics.Table 1Patient demographics and baseline characteristicsCharacteristicsMaleFemaleTotalGender, *n* (%)148 (53.2)130 (46.8)278 (100)Caucasian ethnicity, *n* (%)146 (98.6)129 (99.2)275 (98.9)Mean age (SD) at baseline (years)7.7 (2.7)7.0 (2.6)7.4 (2.7)Mean height (SD) at baseline (cm)112.44 (14.20)108.56 (13.96)110.63 (14.20)Mean height SDS (SD) at baseline−3.38 (0.77)−3.40 (0.78)−3.39 (0.78)Mean HV (SD) at baseline (cm/year)4.09 (1.33)4.43 (1.26)4.25 (1.30)Mean HVSDS (SD) at baseline^a^−1.91 (1.62)−1.72 (1.30)−1.82 (1.48)Mean weight (SD) at baseline (kg)19.3 (6.3)17.0 (5.3)18.3 (6.0)Mean BMI SDSn/an/a−1.54 (1.36)Mean (SD) birth weight SDS−3.2 (1.3)−2.9 (1.1)−3.0 (1.2)Mean (SD) birth length SDS−2.1 (1.6)−1.6 (1.6)−1.8 (1.6)Gestational age (SD) (weeks)38.4 (2.5)38.5 (2.5)38.5 (2.5)*BMI* body mass index, *HV* height velocity, *n/a* not available, *SD* standard deviation, *SDS* standard deviation score^a^Peak-centered data

Impact of rhGH on Diabetes (Primary Endpoint) {#Sec10}
---------------------------------------------

No child developed diabetes mellitus during the first 2 years; no fasting glucose or 2-h OGTT value exceeded the pre-defined limits (\>126 or \>200 mg/dL, respectively). Glucose metabolism data are summarized in Table [2](#Tab2){ref-type="table"}; statistically significant changes (from baseline to Year 1 and Year 2) did occur, but all values remained within normal limits.Table 2Summary of glucose metabolism dataParametersVisitMeanSDMean change from baseline (*P* value)2-h OGTT (mmol/L)Baseline5.281.29Year 15.431.270.15 (*P* = 0.141)Year 25.351.170.08 (*P* = 0.426)Fasting glucose (mmol/L)Baseline4.550.61Year 14.650.560.10 (*P* = 0.009)Year 24.690.510.17 (*P* = 0.0002)Fasting insulin (pmol/L)Baseline35.6534.69Year 153.6835.9317.22 (*P* \< 0.0001)Year 260.2749.9324.63 (*P* \< 0.0001)HbA~1c~ (%)Baseline5.290.50Year 15.370.510.07 (*P* = 0.005)Year 25.370.490.08 (*P* = 0.006)HOMABaseline1.011.03Year 11.571.110.54 (*P* \< 0.0001)Year 21.741.390.76 (*P* \< 0.0001)QUICKIBaseline0.420.10Year 10.380.05−0.04 (*P* \< 0.0001)Year 20.400.35−0.01 (*P* = 0.536)*HbA* ~*1c*~ glycated hemoglobin, *HOMA* homeostasis model assessment, *OGTT* oral glucose tolerance test, *QUICKI* quantitative insulin sensitivity check index, *SD* standard deviation

Impaired glucose tolerance (2-h glucose \>7.8 \<11.1 mmol/L in OGTT) was present in 8/269 patients at 1 year (3.0%) and in 6/249 patients at 2 years (2.4%). Among those patients only 1 patient had impaired glucose tolerance at both time points.

Impact of rhGH on BMI {#Sec11}
---------------------

At baseline, mean (SD) body mass index (BMI) SDS was −1.54 (1.36). BMI SDS initially decreased after start of Omnitrope treatment; at month 6, the mean change from baseline was −0.18 \[95% confidence interval (CI) for mean difference: −0.26, −0.04; *P* \< 0.0001\]. By Year 1, the mean change from baseline in BMI SDS was −0.10 (95% CI for mean difference: −0.17, −0.03; *P* = 0.0065); by Year 2, the mean change from baseline was 0.08 (95% CI for mean difference: −0.01, 0.17; *P* = 0.0922).

Additional Safety Assessments {#Sec12}
-----------------------------

In total, 1093 AEs were reported in 211 (76.2%) children, most of which were mild-to-moderate in intensity (99.3%) and unrelated to study treatment (97.6%). The most commonly occurring AEs are shown in Table [3](#Tab3){ref-type="table"}. In total, 24 drug-related AEs occurred in 17 (6.1%) patients (hypothyroidism, *n* = 7; headache, *n* = 3; impaired fasting plasma glucose, *n* = 3; IGF-I/IGFBP-3 increased, *n* = 2; thyroid-stimulating hormone increased, *n* = 1; puncture site hematoma, *n* = 1; scoliosis, *n* = 1; upper respiratory tract infection, *n* = 1; bronchitis, *n* = 1; impaired glucose tolerance, *n* = 1; pharyngitis, *n* = 1; viral infection, *n* = 1; scarlet fever, *n* = 1). All (except one case of headache) were considered mild in severity, and none required study treatment to be permanently discontinued.Table 3Incidence of adverse events (\>2%) by MedDRA preferred term and intensityPreferred termsIntensity (number of events)Total number of subjectsIncidence per subject-yearMildModerateSeverePharyngitis5918073 (26.40%)0.137Nasopharyngitis653066 (23.80%)0.124Bronchitis305135 (12.60%)0.066Upper respiratory tract infection336034 (12.30%)0.064Varicella183021 (7.60%)0.039Rhinitis152118 (6.50%)0.034Tonsillitis154018 (6.50%)0.034Headache142217 (6.10%)0.032Cough141015 (5.40%)0.028Ear infection150015 (5.40%)0.028Hypothyroidism141015 (5.40%)0.028Pyrexia131014 (5.10%)0.026Urinary tract infection131014 (5.10%)0.026Otitis media104013 (4.70%)0.024Diarrhea102012 (4.30%)0.023Respiratory tract infection101011 (4.00%)0.021Rhinorrhea100010 (3.60%)0.019Scarlet fever8109 (3.20%)0.017Vomiting9009 (3.20%)0.017Abdominal pain7108 (2.90%)0.015Pneumonia7108 (2.90%)0.015Viral infection8108 (2.90%)0.015Acute tonsillitis6107 (2.50%)0.013Dental caries6107 (2.50%)0.013Influenza7007 (2.50%)0.013Lymphadenopathy7007 (2.50%)0.013Gastroenteritis6006 (2.20%)0.011

Serious AEs were reported in 22 patients (7.9%), with only one (severe headache) suspected to be related to study treatment. There have been no reports of malignancies or deaths during the first 2 years of treatment.

Anti-rhGH antibody levels above the cut-off value were measured in 7 patients (2.7%) at Year 1 and in 3 patients (1.2%) at Year 2. Positive test results were transient: only 2 (0.8%) patients had antibodies above the cut-off value in two separate visits.

Efficacy {#Sec13}
--------

Omnitrope treatment was effective, as shown by various height parameters. Mean HSDS is shown in Fig. [1](#Fig1){ref-type="fig"}, and mean HVSDS in Fig. [2](#Fig2){ref-type="fig"}. Catch-up growth continued after 2 years, with a mean HVSDS of 2.23.Fig. 1Mean (95% CI) height SDS during 2 years of treatment with Omnitrope^®^. *CI* confidence interval, *SDS* standard deviation scoreFig. 2Mean (95% CI) height velocity SDS during 2 years of treatment with Omnitrope^®^. *CI* confidence interval, *SDS* standard deviation score

Increases in both BA and height age (HA) were greater than 2 years (with HA increasing more than BA), indicating ongoing true catch-up growth as a result of Omnitrope treatment. Development of BA and HA in comparison with chronological age (CA) between baseline and 2 years (mean ratios for overall study population) was as follows: ΔBA/ΔCA was 1.25 (*P* \< 0.001); ΔHA/ΔCA 1.34 (*P* \< 0.001); ΔHA/ΔBA 1.29 (*P* \< 0.001).

At baseline, 52 patients had IGF-I SDS values below −2, and only one patient had a value greater than +2. At Year 2, IGF-I levels were available for 240 patients; of these, two patients had an SDS value below −2 and 39 patients had a value greater than +2. Also at Year 2, IGF-I/IGFBP-3 values were available for 238 patients; of these, two patients had an SDS value below −2 and 25 patients had a value greater than +2. IGF-I levels increased relatively more than IGFBP-3 levels, resulting in a rising IGF-I/IGFBP-3 ratio (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}).Fig. 3Mean (95% CI) IGF-I SDS (**a**) and IGFBP-3 SDS (**b**) during 2 years of treatment with Omnitrope^®^. *CI* confidence interval, *IGFBP*-*3* insulin-like growth factor-binding protein 3, *IGF*-*I* insulin-like growth factor I, *SDS* standard deviation scoreFig. 4Mean (95% CI) IGF-I/IGFBP-3 ratio during 2 years of treatment with Omnitrope^®^. *CI* confidence interval, *IGFBP*-*3* insulin-like growth factor-binding protein 3, *IGF*-*I* insulin-like growth factor I, *SDS* standard deviation score

Discussion {#Sec14}
==========

The primary objective of this study is to assess the effect of rhGH (Omnitrope) treatment on the development of diabetes in short children born SGA. Short children born SGA are thought to be at heightened risk of metabolic abnormalities, characterized by compensated insulin resistance without obvious abnormality of fasting or post-prandial glucose \[[@CR13]\]. The insulin-antagonistic effects of GH treatment could potentially increase the risk of developing type 2 diabetes in children born SGA. In this second interim analysis, no patients developed diabetes during 2 years of rhGH treatment. Fasting plasma glucose and stimulated glucose (OGTT) remained relatively stable over 2 years of rhGH treatment. These 2-year data are consistent with previous studies on the effects of rhGH treatment on glucose tolerance and insulin sensitivity in children born SGA \[[@CR14], [@CR15]\]. Our findings are also consistent with the previously proposed concept of a compensatory hyperinsulinemia that counters the GH-mediated increase in insulin resistance and maintains normal glucose regulation during treatment \[[@CR16]\]. In addition, our data indicate no adverse alterations in body mass after 2 years of Omnitrope treatment; again, this is in line with other long-term studies of rhGH treatment in children born SGA \[[@CR17]\].

The safety profile of rhGH in SGA children is generally recognized as good \[[@CR3]\], and data from this 2-year analysis support this assertion. In the 1-year interim analysis, the incidence of treatment-related hypothyroidism and headache was 2.5% and 1.1%, respectively \[[@CR10]\]; no additional cases were reported after 2 years of rhGH treatment. The incidence of anti-rhGH antibodies after 2 years of treatment was also low, consistent with findings from long-term studies with Omnitrope in children with GH deficiency \[[@CR18], [@CR19]\].

According to consensus guidelines, a change in HVSDS of more than +0.5 within the first year of GH treatment is considered to be a positive growth response \[[@CR4]\]. In the present study, HVSDS had to be at least +1 after the first year of treatment for patients to be eligible to continue with therapy; therefore, all patients regarded as responders in the present study achieved a positive growth response as defined in the consensus guidelines. The improvement in growth parameters observed over 2 years' treatment with Omnitrope compares well with improvements reported in other studies of various rhGH products in short children born SGA \[[@CR13], [@CR14]\].

Possible study limitations include the lack of a control group and the age of patients when rhGH treatment was initiated (most were aged ≥4 years). However, the clear treatment benefits observed in the majority of patients (increase in HV and net height gain) suggest that this is a population that is responsive to rhGH therapy.

Conclusions {#Sec15}
===========

At this 2-year follow-up, no patient had developed diabetes during rhGH treatment and there were no concerning or clinically relevant safety findings. Omnitrope treatment was effective, with most patients showing continuous catch-up growth after 2 years. These data, in a large international cohort of children born SGA, are consistent with a positive risk--benefit ratio for Omnitrope.
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